|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/14/22 Quantrx Biomedical Corp. 10-Q 9/30/22 39:1.8M M2 Compliance LLC/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 370K
2: EX-31 Certification -- §302 - SOA'02 HTML 17K
3: EX-32 Certification -- §906 - SOA'02 HTML 14K
9: R1 Cover HTML 60K
10: R2 Balance Sheets HTML 84K
11: R3 Balance Sheets (Parenthetical) HTML 32K
12: R4 Statements of Operations (Unaudited) HTML 61K
13: R5 Statements of Cash Flows (Unaudited) HTML 61K
14: R6 Statements of Stockholders' Equity (Unaudited) HTML 38K
15: R7 Description of Business and Basis of Presentation HTML 25K
16: R8 Management Statement Regarding Going Concern HTML 19K
17: R9 Summary of Significant Accounting Policies HTML 37K
18: R10 Convertible Notes Payable HTML 30K
19: R11 Shareholder Loan HTML 16K
20: R12 Related Party Transactions HTML 19K
21: R13 Preferred Stock HTML 26K
22: R14 Common Stock, Options and Warrants HTML 24K
23: R15 Subsequent Events HTML 16K
24: R16 Summary of Significant Accounting Policies HTML 47K
(Policies)
25: R17 Convertible Notes Payable (Tables) HTML 20K
26: R18 Description of Business and Basis of Presentation HTML 16K
(Details Narrative)
27: R19 Management Statement Regarding Going Concern HTML 15K
(Details Narrative)
28: R20 Summary of Significant Accounting Policies HTML 33K
(Details Narrative)
29: R21 Schedule of Convertible Notes Payable (Details) HTML 24K
30: R22 Convertible Notes Payable (Details Narrative) HTML 29K
31: R23 Shareholder Loan (Details Narrative) HTML 15K
32: R24 Related Party Transactions (Details Narrative) HTML 18K
33: R25 Preferred Stock (Details Narrative) HTML 45K
34: R26 Common Stock, Options and Warrants (Details HTML 29K
Narrative)
37: XML IDEA XML File -- Filing Summary XML 63K
35: XML XBRL Instance -- form10-q_htm XML 339K
36: EXCEL IDEA Workbook of Financial Reports XLSX 47K
5: EX-101.CAL Inline XBRL Taxonomy Extension Calculation XML 77K
Linkbase Document -- qtxb-20220930_cal
6: EX-101.DEF Inline XBRL Taxonomy Extension Definition Linkbase XML 142K
Document -- qtxb-20220930_def
7: EX-101.LAB Inline XBRL Taxonomy Extension Label Linkbase XML 365K
Document -- qtxb-20220930_lab
8: EX-101.PRE Inline XBRL Taxonomy Extension Presentation XML 288K
Linkbase Document -- qtxb-20220930_pre
4: EX-101.SCH Inline XBRL Taxonomy Extension Schema Document -- XSD 54K
qtxb-20220930
38: JSON XBRL Instance as JSON Data -- MetaLinks 171± 235K
39: ZIP XBRL Zipped Folder -- 0001493152-22-031830-xbrl Zip 92K
Exhibit 31
CERTIFICATION OF PRINCIPAL EXECUTIVE AND FINANCIAL OFFICER PURSUANT TO
EXCHANGE ACT RULE 13A-14(A)
I, Shalom Hirschman, certify that:
1. I have reviewed this Quarterly report on Form 10-Q of QuantRx Biomedical Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financing reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
| Date: November 14, 2022 | /s/ Shalom Hirschman |
| Shalom Hirschman | |
| Principal Executive and Financial Officer |
C:
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 11/14/22 | None on these Dates | ||
| For Period end: | 9/30/22 | |||
| List all Filings | ||||